Skip to main content
. Author manuscript; available in PMC: 2013 Sep 23.
Published in final edited form as: Cancer. 2010 Oct 1;116(19):4613–4621. doi: 10.1002/cncr.25350

Table 1.

Grade 2 to 4 Toxicities

Toxicity Acute (n=64),a Grade Late (n=60),b Grade 1 Year (n=59),c Grade 2 Years (n=58),c Grade 3 Years (n=47),c Grade 4 Years (n=37),c Grade 5 Years (n=34),c Grade
2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4
Hematologic 3 (4.7%) 9(14.1%) 50(78.1%) 3 (5.0%) 1 (1.7%) 8 (13.3%) 2 (3.4%) 1 (1.7%) 7 (11.9%) 1 (1.7%) 0 2 (3.4%) 0 0 0 0 0 0 0 0 0
Infection 9(14.1%) 14(21.9%) 3 (4.7%) 4 (6.7%) 3 (5.0%) 1 (1.7%) 4 (6.8%) 3(5.1%) 1 (1.7%) 1 (1.7%) 0 0 0 0 0 0 0 0 0 1 (2.9%) 0
Skin 22 (34.4%) 18(28.1%) 3 (4.7%) 2 (3.3%) 2 (3.3%) 0 1 (1.7%) 2 (3.4%) 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0
Mucous membrane 9(14.1%) 1 (1.6%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Subcutaneous tissue 0 0 1 (1.6%) 1 (1.7%) 1 (1.7%) 1 (1.7%) 1 (1.7%) 1 (1.7%) 1 (1.7%) 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0
Hepatic 4 (6.3%) 0 0 1 (1.7%) 0 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Diarrhea 8(12.5%) 3 (4.7%) 0 1 (1.7%) 0 0 0 0 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0
Nausea/vomiting 29 (45.3%) 5 (7.8%) 2 (3.1%) 2 (3.3%) 0 0 2 (3.4%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other gastrointestinal 5 (7.8%) 3 (4.7%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Neurological 5 (7.8%) 2 (3.1%) 0 2 (3.3%) 0 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pain 9(14.1%) 1 (1.6%) 1 (1.6%) 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 (2.9%) 0 0
Genitourinary 3 (4.7%) 1 (1.6%) 0 2 (3.3%) 0 0 1 (1.7%) 0 0 0 0 0 0 0 0 1 (2.7%) 0 0 0 0 0
Respiratory 2 (3.1%) 0 1 (1.6%) 1 (1.7%) 0 1 (1.7%) 1 (1.7%) 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0 0
Cardiac 0 0 1 (1.6%) 1 (1.7%) 1 (1.7%) 0 1 (1.7%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fever 8(12.5%) 1 (1.6%) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Joint 1 (1.6%) 0 0 3 (5.0%) 1 (1.7%) 0 2 (3.4%) 0 0 1 (1.7%) 0 0 1 (2.1%) 0 0 0 1 (2.7%) 0 0 0 0
Peripheral nerves 1 (1.6%) 0 0 1 (1.7%) 2 (3.3%) 0 1 (1.7%) 1 (1.7%) 0 0 1 (1.7%) 0 0 1 (2.1%) 0 0 0 0 0 0 0
Vascular 1 (1.6%) 2 (3.1%) 0 2 (3.3%) 1 (1.7%) 0 1 (1.7%) 1 (1.7%) 0 0 0 0 1 (2.1%) 0 0 0 0 0 0 0 0
Other 20 (31.3%) 6 (9.4%) 3 (4.7%) 5 (8.3%) 0 2 (3.3%) 5 (8.5%) 0 0 0 0 1 (1.7%) 0 0 1 (2.1%) 0 0 0 2 (5.9%) 0 0
a

The acute period is ≤6 months from the initiation of radiotherapy.

b

The late period is >6 months from initiation of radiotherapy.

c

The yearly rates are measured from the initiation of radiotherapy using intervals of ±6 months